-
GSK plc (NYSE:GSK) Q2 2025 Earnings Call Transcript
01 Aug 2025 12:19 GMT
… Waterhouse: Thank you, Luke. Our HIV portfolio continues to deliver exceptional … largely driven by a favorable ViiV CCL movement, predominantly due to … Glaxosmithkline Plc (NYSE:GSK) Follow Glaxosmithkline Plc (NYSE:GSK) We may use …
-
Aurobindo, Cipla and Viatris to make long acting injectable for HIV treatment
28 Jul 2025 21:30 GMT
… HIV treatment in 133 countries, per The Hindu report.
This follows ViiV Healthcare … , a company focused on HIV medicines and majority owned by GSK with Pfizer … injectable cabotegravir + rilpivirine as an HIV treatment option, the report said …
-
ViiV Healthcare extends licensing agreement with Medicines Patient Pool for generic HIV treatment
18 Jul 2025 17:36 GMT
ViiV Healthcare, a global specialist HIV company majority owned by GSK, with Pfizer and … those most impacted by HIV.”
[Related: ViiV Healthcare, Medicines Patent Pool … provide access to HIV prevention medications] …
-
PrEP Adherence Linked to Area Deprivation Index in Ohio
07 Aug 2025 04:11 GMT
… Sciences, Inc), and cabotegravir (Apretude; ViiV Healthcare), or their generic versions, was … ://www.hiv.gov/hiv-basics/hiv-prevention/using … H, Martinez KA. Variation in HIV pre-exposure prophylaxis (PrEP) adherence …
-
ViiV Healthcare phase IIIb VOLITION study data shows 89% of treatment-naïve people with HIV choose to switch to long-acting injectable vocabria + rekambys from daily pills after achieving rapid viral suppression
16 Jul 2025 07:59 GMT
GSK plc announced ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer … ambition of ending HIV and AIDS.”
Data summary from ViiV Healthcare and partner studies … deeper and broader interest in HIV and AIDS than any company has …
-
STAT+: ViiV expands licensing deal for its HIV drug in low-income countries
16 Jul 2025 03:35 GMT
… ViiV Healthcare has announced steps to widen access to a sought-after HIV … known as cabotegravir, covered HIV prevention, but will now … long-acting rilpivirine, another HIV medicine that is made by … as a treatment option for HIV.
STAT+ Exclusive Story
Already …
-
ViiV expands licence to allow generic HIV treatment production for low-income countries
15 Jul 2025 22:51 GMT
… ViiV Healthcare, the HIV-focused joint venture majority owned by GSK, … treatment," said ViiV CEO Deborah Waterhouse. … Global Fund to Fight AIDS, Tuberculosis and Malaria … HIV medicines in the Global South.
ViiV is majority-owned by GSK, with Pfizer …
-
ViiV Healthcare data show 89% of treatment-naïve people with HIV choose to switch to long-acting injectable Vocabria + Rekambys from daily pills after achieving rapid viral suppression
15 Jul 2025 09:24 GMT
… GSK) announced ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and … ambition of ending HIV and AIDS.”
Data summary from ViiV Healthcare and partner studies … deeper and broader interest in HIV and AIDS than any company has …
-
ViiV Healthcare extends voluntary licensing agreement with Medicines Patent Pool to enable access to innovative long-acting injectable HIV treatment
15 Jul 2025 09:24 GMT
… : GSK) announced ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and … deeper and broader interest in HIV and AIDS than any company has …
-
WHO’s lenacapavir guidance a ‘great moment’ in HIV fight
25 Jul 2025 21:54 GMT
… the various recommendations surrounding HIV treatment and prevention … but other important HIV drugs including ViiV Healthcare’s long … Global Fund to Fight AIDS, Tuberculosis and Malaria. … health, pharmaceuticals, activists and HIV, representing “a good story …
About
© 1995-2025